The cardiovascular safety of saxagliptin is approved by the FDA
April 17, 2015 Source: Xinhuanet
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];The advisory committee meeting was based on SAVOR's findings. SAVOR is a large, randomized, double-blind study that evaluates saxagliptin in standard glucose-lowering patients for adults with type 2 diabetes who are at risk for cardiovascular disease. The program is based on the cardiovascular safety of combination therapy.
AstraZeneca is a global innovation-driven biopharmaceutical company focused on the development, development and commercialization of prescription drugs, with a focus on cardiovascular, metabolic, respiratory, inflammatory, autoimmune, oncology, infection and neurological treatments. With operations in more than 100 countries, AstraZeneca's innovative drugs benefit millions of patients worldwide.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharmas.com